Navigation Links
LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
Date:4/20/2009

COPENHAGEN, April 20 /PRNewswire/ -- Santaris Pharma announced today promising findings on the in vitro and in vivo activity of microRNA-targeted therapeutics against cancer developed on the basis of its proprietary Locked Nucleic Acid (LNA) Drug Platform. In both in vitro and in vivo models Santaris Pharma's cancer targeted LNA-antimiR(R)'s demonstrated outstanding recognition and inhibition of disease-associated microRNAs due to their high specificity and affinity. The findings were presented this week at the AACR Meeting in Colorado at a symposium on microRNAs and human cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"Santaris Pharma has made significant progress in advancing a rich pipeline of clinical and preclinical drug candidates targeting disease related RNAs, including microRNAs," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer. "These results are another demonstration of the fact that our small, single-stranded oligonucleotides have great potential in relation to the development of microRNA targeting therapeutics within a range of disease areas."

Santaris Pharma is a leader within microRNA research and is collaborating with scientists world-wide to exploit the advantages of the LNA chemistry to design and develop effective and safe antimiRs against a broad range of diseases, including cancer.

Santaris Pharma (founded in 2003) is a privately held clinical stage biopharmaceutical company developing new classes of RNA medicines targeting disease-related mRNAs and miRNAs based on its proprietary LNA chemistry. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. Santaris Pharma is leveraging its highly effective and efficient Drug Discovery Engine to generate lead LNA drug candidates against a broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development. Santaris Pharma has since its inception raised nearly $100 million through private financing and up-front payments.

    For further information please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-20488384
    E-mail: rmk@santaris.com
   http://www.santaris.com


'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
2. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. TauTaTis Discovers Potent Inhibitor of Parkinsons Disease Gene Activity
5. Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
6. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
7. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
8. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
9. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
10. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
11. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... focused on quality, regulatory and technical consulting, provides a free webinar ... presented on July 13, 2016 at 12pm CT at no charge. , Incomplete ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
Breaking Biology Technology:
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):